title: Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma.
abstract: OBJECTIVE
  There were 49 patients studied, coming from The Liver Unit at the "Hospital das Clinicas da Faculdade de Medicina da USP (N=41) and from "Prof. Dr. Angelita Habr-Gama and Joaquim Gama-Rodrigues Surgery Institute", SP (N=8); all of which had hepatic metastasis of colorectal adenocarcinoma, with no evidence of concurrent metastasis in any other organs and were submitted to surgical treatment, during the period of 1992 to 2002, with the aim of analyzing the immunoexpression of the p53, ki-67, p16 and molecular markers in order to relate the disease-free period with the prognosis.
  
  
  METHODS
  The patient's clinical data were analyzed retrospectively for verification of information such as age, gender, size of the hepatic metastasis and/or the largest lesion, number of satellite nodules resected and compromised, margin of resection free from neoplasia.
  
  
  RESULTS
  The immunoexpression of the p53 was associated with the shortest period of life free from disease (p = 0.04). The proliferation marker ki-67 was not associated with the reduction of the disease-free interval and survival; the immunoexpression of the proliferation marker p16 was not associated with the reduction of disease-free period and survival, however, it was associated with hepatic metastasis synchronism. In patients who received postoperative systemic chemotherapy with 5-FU and leucovorin, the immunoexpression on the hepatic metastasis was not associated with a longer disease-free interval.
  
  
  CONCLUSIONS
  Molcular markers may be useful to evaluate hepatic metastasis of colorectal Adenocarcinoma.
authors.affiliation: Department of Gastroenterology, University of Sdo Paulo, School of Medicine, Brazil. jclaudio3572@terra.com.br
authors.forename: J C
authors.initials: JC
authors.lastname: Murad
authors.forename: U
authors.initials: U
authors.lastname: Ribeiro
authors.forename: A V
authors.initials: AV
authors.lastname: Safatle-Ribeiro
authors.forename: E
authors.initials: E
authors.lastname: Parra
authors.forename: V
authors.initials: V
authors.lastname: Rawet
authors.forename: C E
authors.initials: CE
authors.lastname: Corbett
authors.forename: V A
authors.initials: VA
authors.lastname: Ferreira
authors.forename: V
authors.initials: V
authors.lastname: Pugliese
authors.forename: W A
authors.initials: WA
authors.lastname: Saad
authors.forename: A
authors.initials: A
authors.lastname: Habr-Gama
authors.forename: J
authors.initials: J
authors.lastname: Gama-Rodrigues
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000473:pathology*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013940:Thymidylate Synthase / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53; D013940:Thymidylate Synthase